NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 124 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $89,529 | -41.3% | 83,672 | +42.2% | 0.00% | – |
| Q2 2023 | $152,398 | -52.9% | 58,841 | -25.8% | 0.00% | – |
| Q1 2023 | $323,638 | +1.0% | 79,323 | +24.3% | 0.00% | – |
| Q4 2022 | $320,276 | -79.9% | 63,800 | -47.7% | 0.00% | – |
| Q3 2022 | $1,596,000 | +119.8% | 121,968 | +115.4% | 0.00% | – |
| Q2 2022 | $726,000 | +104.5% | 56,619 | +235.0% | 0.00% | – |
| Q3 2021 | $355,000 | +28.2% | 16,900 | +20.3% | 0.00% | – |
| Q2 2021 | $277,000 | -63.2% | 14,047 | -45.8% | 0.00% | – |
| Q1 2021 | $753,000 | -50.5% | 25,900 | -48.4% | 0.00% | – |
| Q4 2020 | $1,522,000 | +745.6% | 50,236 | +343.6% | 0.00% | – |
| Q3 2020 | $180,000 | -25.0% | 11,324 | -6.7% | 0.00% | – |
| Q2 2020 | $240,000 | +70.2% | 12,133 | +6.2% | 0.00% | – |
| Q1 2020 | $141,000 | – | 11,427 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |